Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer

Background Early detection of ovarian cancer could significantly improve patient outcomes. Cancer antigen 125 (CA 125) is elevated in sera from approximately 60% of patients with early‐stage (I/II) disease. Sensitivity might be improved through the combination of CA 125 with other biomarkers. Among...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2020-02, Vol.126 (4), p.725-736
Hauptverfasser:	Yang, Wei‐Lei, Lu, Zhen, Guo, Jing, Fellman, Bryan M., Ning, Jing, Lu, Karen H., Menon, Usha, Kobayashi, Makoto, Hanash, Samir M., Celestino, Joseph, Skates, Steven J., Bast, Robert C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antigens antigen‐autoantibody complexes Autoantibodies Autoantibodies - blood Autoantibodies - immunology Biomarkers Biomarkers, Tumor - blood CA-125 Antigen - blood Cancer cancer antigen 125 (CA 125) Cancer screening Complementarity early detection Early Detection of Cancer - methods Early Detection of Cancer - statistics & numerical data Epididymis Female Health risk assessment Health risks human epididymis protein 4 (HE4) Humans Immunoassays Lead time Mass Screening - methods Mass Screening - statistics & numerical data Medical screening Middle Aged Neoplasm Staging Oncology Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - diagnosis Proteins ROC Curve WAP Four-Disulfide Core Domain Protein 2 - analysis WAP Four-Disulfide Core Domain Protein 2 - immunology Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!